eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

GlaxoSmithKline Consumer Healthcare
980 Great West Road, Brentford, Middlesex, TW8 9GS
Telephone: +44 (0)20 8047 5000
Medical Information Direct Line: +44 (0)20 8047 2500
Medical Information e-mail: customer.relations@gsk.com
Customer Care direct line: +44 (0)20 8047 2700
Medical Information Fax: +44 (0)20 8047 6860

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 18/03/2009
SPC Joy-rides Tablets


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Joy-rides Tablets


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active constituent

Hyoscine hydrobromide 0.15 mg

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

A raspberry flavoured chewed tablet for oral administration.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Anti-muscarinic. For the prevention of motion sickness.


Go to top of the page
4.2 Posology and method of administration

Route of administration: Oral.

Adults over 13 years:

2 tablets 20 minutes before start of the journey. Maximum 4 tablets in 24 hours.

Children:

20 minutes before journey. 7 - 12 years: 1 -2 tablets. 4 - 7 years: 1 tablet. Maximum 2 tablets in 24 hours. 3 – 4 years: half a tablet. Maximum 1 tablet in 24 hours.

Not recommended under 3 years except on medical advice.

Ideally taken 20 minutes before the start of the journey. However, still effective if taken at onset of nausea or after the journey has begun.


Go to top of the page
4.3 Contraindications

Glaucoma.


Go to top of the page
4.4 Special warnings and precautions for use

Do not exceed the stated dose. Avoid alcoholic drink.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

The actions of Hyoscine Hydrobromide may be potentiated by concurrent phenothiazines, tricyclic antidepressants or alcohol. Aluminium hydroxide preparations may reduce absorption of Hyoscine Hydrobromide. The actions may of tricyclic antidepressants may be potentiated by concurrent Hyoscine Hydrobromide.


Go to top of the page
4.6 Pregnancy and lactation

Safety in pregnancy has not been established, but the drug has been used widely for many years without apparent ill effect. However, the normal precautions of avoiding unnecessary medication especially in the first trimester of pregnancy should be observed.

Hyoscine hydrobromide can cross the placenta and appears in trace quantities in breast milk.


Go to top of the page
4.7 Effects on ability to drive and use machines

May cause drowsiness, if affected do not drive or operate machinery.


Go to top of the page
4.8 Undesirable effects

Some patients may experience dry mouth, dizziness, blurred vision and difficulty with micturition.


Go to top of the page
4.9 Overdose

The main symptoms are sleepiness, dry mouth, rapid heart rate, palpitation, dilated pupils. Take measures to limit intestinal absorption immediately. Parasympathetic agents such as physotigmine should be used as necessary. Do not use phenothiazines.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

The Atropine like actions of Hyoscine hydrobromide are well known. The site of action in preventing motion sickness is thought to be either on the cortex or more peripherally on the vestibular apparatus.


Go to top of the page
5.2 Pharmacokinetic properties

Hyoscine is rapidly absorbed from the gastro-intestinal tract. About 1 % of an oral dose is eliminated as such in the urine. Traces are found in various secretions, including milk.


Go to top of the page
5.3 Preclinical safety data

None.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Mannitol

Erythrosine (E.127) Lake

Povidone

Raspberry Flavour Trusil J7551

Microcrystalline cellulose

Magnesium stearate


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C in a dry place.


Go to top of the page
6.5 Nature and contents of container

Tablets are individually sealed in strips of 12, or as 2 strips of 6, between 2 layers of 0.25 mm soft aluminium foil/0.25 mm polyethylene. Strips are packed in decorated, folding boxboard cartons.


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
Administrative Data

Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Stafford-Miller Limited

980 Great West Road

Brentford, Middlesex

TW8 9GS

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 0036/5004R


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

First granted 22 July 1973.

Last renewed 12 April 1996.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

17/09/2008



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/19795/SPC/


Active Ingredients/Generics

 
  hyoscine hydrobromide